Sökning: onr:"swepub:oai:DiVA.org:uu-433614" >
Cytoreductive surge...
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with or without early post-operative intraperitoneal chemotherapy for appendix neoplasms with peritoneal metastases : A propensity score analysis
-
- Soucisse, Mikael L. (författare)
- Univ Montreal, Dept Surg, Hop Maisonneuve Rosemont, 5415 Boul Assompt, Montreal, PQ H1T 2M4, Canada.
-
- Fisher, Oliver (författare)
- Univ New South Wales, Dept Surg, St George Hosp, Sydney, NSW, Australia.
-
- Liauw, Winston (författare)
- Univ New South Wales, Dept Med Oncol, St George Hosp, Sydney, NSW, Australia.
-
visa fler...
-
- Ghanipour, Lana (författare)
- Uppsala universitet,Gastrointestinalkirurgi
-
- Cashin, Peter, 1984- (författare)
- Uppsala universitet,Gastrointestinalkirurgi
-
visa färre...
-
Univ Montreal, Dept Surg, Hop Maisonneuve Rosemont, 5415 Boul Assompt, Montreal, PQ H1T 2M4, Canada Univ New South Wales, Dept Surg, St George Hosp, Sydney, NSW, Australia. (creator_code:org_t)
- Elsevier, 2021
- 2021
- Engelska.
-
Ingår i: European Journal of Surgical Oncology. - : Elsevier. - 0748-7983 .- 1532-2157. ; 47:1, s. 157-163
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: Early post-operative intraperitoneal chemotherapy (EPIC) can be used after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with resectable peritoneal metastases (PM). Whether EPIC adds any benefit is debatable.Methods: We performed a retrospective case-control analysis of patients with PM of appendiceal origin treated by CRS + HIPEC +/- EPIC at Uppsala University Hospital between 2004 and 2012. The 206 patients were divided into two groups depending on if they received EPIC or not. The two groups were propensity-matched with a 1:1 ratio. The patients in the EPIC group were mostly operated in the first three years of the unit's experience.Results: After matching, 76 patients were left in each group. The groups were similar, except for the proportion of histological subtypes (p = 0.021) and chemotherapy agents used for HIPEC (0.017). Survival outcomes were stratified by histology. The patients who received EPIC had a longer hospital and ICU length of stay (15.71 vs 14.28 days, p = 0.049), (1.45 vs 1.05 days, p = 0.002), respectively. Post-operative complications were similar in both groups. Overall Survival (OS) and recurrence-free survival (RFS) did not differ for the patients with low-grade histology. The patients with high-grade tumors who received EPIC had a significantly worse OS (p = 0.0088) while having the same RFS as the patients who did not receive EPIC.Conclusion: Our results suggest there is no benefit of EPIC in patients with advanced appendiceal tumors while increasing hospital and ICU length of stays. A suboptimal group matching might influence our results. (C) 2020 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Nyckelord
- Early post-operative intraperitoneal chemotherapy
- EPIC
- Pseudomyxoma peritonei
- PMP
- Appendix neoplasm
- Cytoreductive surgery
- HIPEC
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas